Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursolic Acid for Myopenia and Insulin Resistance in Chronic SCI
NCT05776862Phase 2Completed
- Sponsor
- University of Miami
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in muscle atrophy and insulin resistance (IR), sponsored by University of Miami. Primary endpoints: Change in Muscle Mass Using Dual X-ray Absorptiometry at 12 weeks, Changes in Peak Isokinetic Strength at 12 weeks and 1 more. Started Mar 2023; status: completed.
02
Conditions
muscle atrophyinsulin resistance (IR)
Beyond the preview
Go deeper on NCT05776862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776862.